Compare Johnson & Johnson (JNJ) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Johnson & Johnson trades at $260.64 (market cap $618.09B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.38 (market cap $28.50B). The key difference: Johnson & Johnson is far larger — about 21.7× iShares iBoxx $ Inv Grade Corporate Bond ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| JNJ | LQD | |
|---|---|---|
Market Cap | $618.09B | $28.50B |
Volume | 6,050,983 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $278.43 | $112.91 |
52-Week Low | $186.00 | $101.83 |
Typical Hold Time | 129 Days | 125 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
LQD trades at $102.39 with a slight 0.26% daily gain amid a challenging bond market environment. The ETF faces bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September (Defense World, 2026-10-01) and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs.
The outlook remains cautious with rising bond yields creating headwinds for corporate bond ETFs. While LQD offers a 4.8% yield with high-quality portfolio exposure, the weak investment thesis noted by Seeking Alpha (2026-09-22) and substantial short interest growth suggest near-term pressure. Investors should monitor Fed policy decisions and corporate bond market stability for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
